Document is current
Any future updates will be listed below
-
Authors
Roustit, Matthieu https://orcid.org/0000-0003-4475-1626
Chaumais, Marie-Camille
Chapuis, Claire
Gairard-Dory, Anne
Hadjadj, Caroline
Chanoine, Sébastien
Allenet, Benoît
Sitbon, Olivier
Pison, Christophe
Bedouch, Pierrick
,
Dromer, Claire
Duconge, Séverine
Glavieux, Alan
Saux, Marie-Claude
Yeni, Sami
Demeyer, Christelle
Frachon, Irène
Lorillon, Philippe
Bastin, Anne
Bouvaist, Hélène
Camara, Boubou
Chat, Céline
Coste, Marie
Delamare, Marion
Gonnet, Nicolas
Jondot, Marie
Lepelley, Marion
Lotito, Adrien
Quetant, Sébastien
Odin, Emmanuelle
Robert, Christel
Raymond, Christel Saint
Salvat, Muriel
Saunier, Carole
Belaiche, Stéphanie
Hachulla, Eric
Lefebvre, Marie-Noelle
Wojtasik, Géraldine
Chauvet, Pierre
Creach, Catherine
Danner, Isabelle
Fayad, Nadia
Feldman, David
Haloun, Alain
Trainaud, Alexandra
Viaud, Valérie
Babin, Aline
Le Duff, Alexia
Lemoigne, Franck
Muller, Katia
Bruère, Isabelle
Coulon, Hélène
Humbert, Marc
Jaïs, Xavier
Jobard, Marion
Lott, Marie-Catherine
Montani, David
Savale, Laurent
Simmoneau, Gérald
Bauer, Fabrice
Benmokhtar, Emmanuelle
Huet, Estelle
Philippe, Sandrine
Varin, Remi
Canuet, Matthieu
Wolff, Thomas
Antier, Daniel
Crenn, Isabelle
Collet, Elisabeth
Anne, Delagarenne
Magro, Pascal
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01038284 at ClinicalTrials.govDocuments that mention this clinical trial
Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial
https://doi.org/10.1007/s11096-020-01047-8
-
Funding
Funding for this research was provided by:
French Society for Clinical Pharmacy
Grenoble University Hospital
Actelion Pharmaceuticals
Pfizer
GlaxoSmithKline
- License Information
-
More Information
Article History
Received: 23 April 2019
Accepted: 27 April 2020
First Online: 21 May 2020
Conflicts of interest
: MR has received research grants for the present study from Grenoble University Hospital, the French Society for Clinical Pharmacy (SFPC), Actelion Pharmaceuticals, Pfizer, and GlaxoSmithKline, paid to his institution. CC reports personal fees from Boehringer, personal fees from Baxter, outside the context of the submitted work. SC reports non-financial support from GSK France, outside the submitted work. OS reports grants, personal fees and non-financial support from Actelion Pharmaceuticals, grants and personal fees from Bayer HealthCare, grants, personal fees and non-financial support from GlaxoSmithKline, personal fees from Merck, grants and personal fees from Pfizer, personal fees from United Therapeutics, outside the context of the submitted work. CP reports grants, personal fees and non-financial support from Actelion Pharmaceuticals, grants and personal fees from Pfizer, grants and personal fees from GlaxoSmithKline, grants and personal fees from Bayer, during the conduct of the study. MCC and PB report non-financial support and personal fees from Actelion Pharmaceuticals, outside the context of the submitted work. AGD, CH and BA have no conflict of interests to declare.
